AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8852910 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated patients (combined interferon groups)
Number of subjects: 31
Study 1479270 — intervention group
Group type: EXPERIMENTAL
Intervention: Freshening the edge of the defect and placing a small piece of 0.13 mm silastic sheeting over the defect
Number of subjects: 152
Study 1479270 — intervention group
Group type: COMPARATOR
Intervention: Freshening the edge of the defect only
Number of subjects: 152
Study 6543431 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 30
Study 6543431 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole
Number of subjects: 30
Study 29479727 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium hydroxide 10%
Number of subjects: 53
Study 29479727 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium hydroxide 15%
Number of subjects: 53
Study 29479727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 26885526 — intervention group
Group type: EXPERIMENTAL
Intervention: HIT (High Intensity Training)
Number of subjects: 120
Study 26885526 — intervention group
Group type: EXPERIMENTAL
Intervention: HIT&P (High Intensity Training with Protein Supplementation)
Number of subjects: 120
Study 26885526 — intervention group
Group type: EXPERIMENTAL
Intervention: HVHIT (High Volume/High Intensity Training)
Number of subjects: 120
Study 26885526 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 120
Study 25626751 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-task OSCE stations (hypothesis-driven physical examination)
Number of subjects: 40
Study 25626751 — intervention group
Group type: COMPARATOR
Intervention: Part-task OSCE stations (examination of a healthy patient)
Number of subjects: 40
Study 23758485 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate once-daily (QD; 900 mg)
Number of subjects: 12
Study 23758485 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate twice-daily (BID; 450 mg)
Number of subjects: 12
Study 23758485 — intervention group
Group type: COMPARATOR
Intervention: Oxcarbazepine BID (450 mg)
Number of subjects: 12
Study 23758485 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate QD, ESL BID, and OXC BID
Number of subjects: 12
Study 19897177 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray (18 or 24 IU)
Number of subjects: 16
Study 19897177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 18199894 — intervention group
Group type: EXPERIMENTAL
Intervention: TZP-101 (20-600 microg/kg)
Number of subjects: 48
Study 18199894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 16775677 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional ultrasound (11.7 MHz linear transducer)
Number of subjects: 34
Study 16775677 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 34
Study 14967872 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate meal (C; 3 g carbohydrate/kg)
Number of subjects: 8
Study 14967872 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoenergetic fat meal (F; 1.3 g fat/kg)
Number of subjects: 8
Study 14967872 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo meal (P; no energy content)
Number of subjects: 8
Study 10840251 — intervention group
Group type: EXPERIMENTAL
Intervention: Information cards (intervention group)
Number of subjects: 76
Study 10840251 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention (control group)
Number of subjects: 76
Study 9085972 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine with propofol
Number of subjects: 124
Study 9085972 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nitroglycerin ointment with plain propofol
Number of subjects: 124
Study 9085972 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nitroglycerin ointment with propofol mixed with lidocaine
Number of subjects: 124
Study 9085972 — intervention group
Group type: COMPARATOR
Intervention: Placebo with plain propofol
Number of subjects: 124
Study 9085972 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol mixed with lidocaine
Number of subjects: 124
Study 8458683 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg, product A)
Number of subjects: 8
Study 8458683 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (20 mg, product B)
Number of subjects: 8
Study 3094054 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana smoking
Number of subjects: 10
Study 3094054 — intervention group
Group type: COMPARATOR
Intervention: Placebo cigarette smoking
Number of subjects: 10
Study 31030229 — intervention group
Group type: EXPERIMENTAL
Intervention: 365 μm holmium laser
Number of subjects: 200
Study 31030229 — intervention group
Group type: COMPARATOR
Intervention: 200 μm holmium laser (Control)
Number of subjects: 200
Study 30439316 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive early bed physical activity (15-30 minutes, twice a day)
Number of subjects: 160
Study 30439316 — intervention group
Group type: COMPARATOR
Intervention: Intermittent pneumatic compression (IPC) (30 minutes, twice a day)
Number of subjects: 160
Study 30439316 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive early bed physical activity
Number of subjects: 160
Study 30439316 — intervention group
Group type: COMPARATOR
Intervention: Intermittent pneumatic compression (IPC)
Number of subjects: 160
Study 27857211 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 36
Study 27857211 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion
Number of subjects: 36
Study 24595965 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 118
Study 24595965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 23539698 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial-opening extension gap
Number of subjects: 277
Study 23539698 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral-opening extension gap
Number of subjects: 277
Study 23539698 — intervention group
Group type: COMPARATOR
Intervention: No asymmetric gap
Number of subjects: 277
Study 20512409 — intervention group
Group type: EXPERIMENTAL
Intervention: Family intervention (SET)
Number of subjects: 126
Study 20512409 — intervention group
Group type: COMPARATOR
Intervention: Group intervention
Number of subjects: 126
Study 20512409 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 126
Study 18345549 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous injection of physiological saline (placebo)
Number of subjects: 29
Study 16943455 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (50 mg/day)
Number of subjects: 14573
Study 16943455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14573
Study 14689793 — intervention group
Group type: EXPERIMENTAL
Intervention: Mairin-P (isoniazid 60 mg, rifampicin 120 mg, pyrazinamide 300 mg, ethambutol hydrochloride 225 mg)
Number of subjects: 0
Study 14689793 — intervention group
Group type: EXPERIMENTAL
Intervention: Mairin-P
Number of subjects: 0
Study 14689793 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment regimens with antituberculous drugs
Number of subjects: 0
Study 11205722 — intervention group
Group type: EXPERIMENTAL
Intervention: Management strategies for advanced CHF
Number of subjects: 0
Study 8880740 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% and ketamine 0.3%
Number of subjects: 18
Study 8880740 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5% only
Number of subjects: 18
Study 1390487 — intervention group
Group type: EXPERIMENTAL
Intervention: PhXA34 0.3 micrograms
Number of subjects: 40
Study 1390487 — intervention group
Group type: EXPERIMENTAL
Intervention: PhXA34 1 microgram
Number of subjects: 40
Study 1390487 — intervention group
Group type: EXPERIMENTAL
Intervention: PhXA34 3 micrograms
Number of subjects: 40
Study 1390487 — intervention group
Group type: EXPERIMENTAL
Intervention: PhXA34 10 micrograms
Number of subjects: 40
Study 1390487 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 40
Study 3100871 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide + orchiectomy
Number of subjects: 334
Study 3100871 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide + LHRH agonist [D‐Trp6]LHRH ethylamide
Number of subjects: 334
Study 3100871 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide alone for previously castrated patients
Number of subjects: 334
Study 3100871 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (Flutamide + LHRH agonist)
Number of subjects: 334
Study 31167902 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol cigarette ban
Number of subjects: 1197
Study 31167902 — intervention group
Group type: EXPERIMENTAL
Intervention: All menthol product ban
Number of subjects: 1197
Study 31167902 — intervention group
Group type: EXPERIMENTAL
Intervention: Green replacement
Number of subjects: 1197
Study 31167902 — intervention group
Group type: COMPARATOR
Intervention: No ban
Number of subjects: 1197
Study 30088473 — intervention group
Group type: EXPERIMENTAL
Intervention: Interceptor® G2 (unwashed)
Number of subjects: 0
Study 30088473 — intervention group
Group type: EXPERIMENTAL
Intervention: Interceptor® G2 (washed 20 times)
Number of subjects: 0
Study 30088473 — intervention group
Group type: COMPARATOR
Intervention: Interceptor® LN (unwashed)
Number of subjects: 0
Study 30088473 — intervention group
Group type: COMPARATOR
Intervention: Interceptor® LN (washed 20 times)
Number of subjects: 0
Study 27936214 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block (post‐tetanic‐count 2‐3)
Number of subjects: 100
Study 27936214 — intervention group
Group type: COMPARATOR
Intervention: Moderate neuromuscular block (train-of-four 1-2)
Number of subjects: 100
Study 25338443 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive treatment group
Number of subjects: 300
Study 25338443 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment group
Number of subjects: 300
Study 22071882 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 39
Study 22071882 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25 mg
Number of subjects: 39
Study 22071882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 22071882 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg and 1.25 mg
Number of subjects: 39
Study 23050889 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured psychoeducation programme
Number of subjects: 109
Study 18523833 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior-stabilized mobile-bearing TKA
Number of subjects: 103
Study 18523833 — intervention group
Group type: COMPARATOR
Intervention: Posterior-stabilized fixed-bearing TKA
Number of subjects: 103
Study 19193602 — intervention group
Group type: EXPERIMENTAL
Intervention: Need to belong (experimental intervention)
Number of subjects: 0
Study 19193602 — intervention group
Group type: EXPERIMENTAL
Intervention: Community acceptance (experimental intervention)
Number of subjects: 0
Study 19193602 — intervention group
Group type: COMPARATOR
Intervention: Control variables (Study 1)
Number of subjects: 0
Study 19193602 — intervention group
Group type: EXPERIMENTAL
Intervention: Causal effect of need to belong (Study 2)
Number of subjects: 0
Study 15896421 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral solution of arginine
Number of subjects: 8
Study 15896421 — intervention group
Group type: COMPARATOR
Intervention: Control solution of amino-acids
Number of subjects: 8
Study 11447774 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusive calcipotriol 50 micrograms/mg ointment applied twice-weekly overnight under occlusion
Number of subjects: 39
Study 11447774 — intervention group
Group type: COMPARATOR
Intervention: Nonocclusive calcipotriol 50 micrograms/mg ointment applied twice-daily
Number of subjects: 39
Study 9746766 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose 6-methylprednisolone (6MPred; 2 mg/kg/d; n = 47)
Number of subjects: 95
Study 9746766 — intervention group
Group type: COMPARATOR
Intervention: High-dose 6-methylprednisolone (6MPred; 10 mg/kg/d; n = 48)
Number of subjects: 95
Study 9746766 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose 6-methylprednisolone (6MPred; 2 mg/kg/d; switched to high-dose after 5 days)
Number of subjects: 95
Study 9746766 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose 6-methylprednisolone (6MPred; 2 mg/kg/d; continued with tapering doses)
Number of subjects: 95
Study 7846423 — intervention group
Group type: EXPERIMENTAL
Intervention: medroxy-progesterone acetate (MPA)
Number of subjects: 0
Study 7846423 — intervention group
Group type: COMPARATOR
Intervention: alpha-interferon (alpha-IFN)
Number of subjects: 0
Study 3167248 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjoint Therapy (8 sessions)
Number of subjects: 116
Study 3167248 — intervention group
Group type: COMPARATOR
Intervention: Advice Counselling (1 session)
Number of subjects: 116
Study 30759089 — intervention group
Group type: EXPERIMENTAL
Intervention: nVNS
Number of subjects: 30
Study 30139465 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen supplementation
Number of subjects: 622
Study 30139465 — intervention group
Group type: COMPARATOR
Intervention: Ambient air
Number of subjects: 622
Study 26936519 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 356
Study 26936519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356
Study 24850059 — intervention group
Group type: EXPERIMENTAL
Intervention: Free vaccination in the FATC (Group B)
Number of subjects: 872
Study 24850059 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Group C)
Number of subjects: 872
Study 24850059 — intervention group
Group type: COMPARATOR
Intervention: Training on HBV epidemiology, risk factors and vaccination (Group A)
Number of subjects: 872
Study 22144699 — intervention group
Group type: EXPERIMENTAL
Intervention: IVMP+IVIG
Number of subjects: 122
Study 22144699 — intervention group
Group type: COMPARATOR
Intervention: IVIG
Number of subjects: 122
Study 18849028 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (20 mg/min) and tetrahydrobiopterin (BH(4)) (500 microg/min)
Number of subjects: 12
Study 18849028 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 12
Study 18849028 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine and BH(4) infusion
Number of subjects: 12
Study 17493109 — intervention group
Group type: EXPERIMENTAL
Intervention: Industry-supported trials (31 of 49, 63%)
Number of subjects: 18238
Study 17493109 — intervention group
Group type: EXPERIMENTAL
Intervention: Industry-supported trials
Number of subjects: 18238
Study 17493109 — intervention group
Group type: COMPARATOR
Intervention: Non-industry trials
Number of subjects: 18238
Study 17493109 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall NRT trials
Number of subjects: 18238
Study 17493109 — intervention group
Group type: EXPERIMENTAL
Intervention: Industry trials after imputation adjustment
Number of subjects: 18238
Study 16202894 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-bonded cardiopulmonary bypass circuits (HBCPB)
Number of subjects: 71
Study 16202894 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonheparin-coated cardiopulmonary bypass circuits and EACA (EACPB)
Number of subjects: 71
Study 16202894 — intervention group
Group type: COMPARATOR
Intervention: Nonheparin-coated bypass circuits and placebo (control)
Number of subjects: 71
Study 12376201 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole alone or in combination with tamoxifen
Number of subjects: 0
Study 12376201 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 0
Study 10411413 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg/day with an oral contraceptive
Number of subjects: 81
Study 10411413 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate 50 mg/day on days 1 to 10 with an oral contraceptive
Number of subjects: 81
Study 10411413 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide 250 mg twice a day
Number of subjects: 81
Study 8866899 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic blood pressure measurements (average of three measurements, sphygmomanometry)
Number of subjects: 1438
Study 8866899 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure measurements (average of morning and evening measurements, semiautomatic device)
Number of subjects: 1438
Study 8866899 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure measurements (automatic readings at 20 min intervals, Spacelabs 90207)
Number of subjects: 1438
Study 8866899 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime average blood pressure
Number of subjects: 1438
Study 8866899 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-time blood pressure
Number of subjects: 1438
Study 8866899 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limit of normality for home blood pressure
Number of subjects: 1438
Study 8866899 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limit of normality for ambulatory blood pressure
Number of subjects: 1438
Study 2185691 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (750 mg every 12 h)
Number of subjects: 12
Study 2185691 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (750 mg every 12 h) and oral rifampin (300 mg every 12 h)
Number of subjects: 12
Study 2185691 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin and rifampin (group B) compared to historical controls
Number of subjects: 12
Study 84900 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% acycloguanosine eye ointment
Number of subjects: 24
Study 84900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 84900 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical acycloguanosine alone
Number of subjects: 24
Study 31120518 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone plus placebo
Number of subjects: 102
Study 31120518 — intervention group
Group type: COMPARATOR
Intervention: Dutasteride
Number of subjects: 102
Study 27859252 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis-, Bacillus megaterium-, and Bacillus pumulus-containing toothpaste, mouthrinse and toothbrush cleaner for 8 weeks
Number of subjects: 40
Study 27859252 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothpaste, mouthrinse and toothbrush cleaner for 8 weeks
Number of subjects: 40
Study 27859252 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis-, Bacillus megaterium-, and Bacillus pumulus-containing products
Number of subjects: 40
Study 27859252 — intervention group
Group type: COMPARATOR
Intervention: Placebo products
Number of subjects: 40
Study 26345602 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA (600 mg qd)
Number of subjects: 45
Study 26345602 — intervention group
Group type: COMPARATOR
Intervention: ALA withdrawal
Number of subjects: 45
Study 23422292 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 87
Study 23422292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 21250901 — intervention group
Group type: EXPERIMENTAL
Intervention: MVM+D (multivitamin and mineral supplement plus vitamin D 1,200 IU/day)
Number of subjects: 61
Study 21250901 — intervention group
Group type: COMPARATOR
Intervention: MVM (multivitamin and mineral supplement)
Number of subjects: 61
Study 21250901 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 1,200 IU/day
Number of subjects: 61
Study 21250901 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 61
Study 19625236 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered antidiabetic drugs (OADs) combination therapies
Number of subjects: 0
Study 19625236 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-tablet OAD combinations
Number of subjects: 0
Study 18177193 — intervention group
Group type: EXPERIMENTAL
Intervention: Revision surgery
Number of subjects: 100
Study 18177193 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonrevision (no surgery)
Number of subjects: 100
Study 18177193 — intervention group
Group type: COMPARATOR
Intervention: Noncleft control
Number of subjects: 100
Study 15057587 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal hemorrhoidectomy with radiofrequency bistoury
Number of subjects: 102
Study 15057587 — intervention group
Group type: COMPARATOR
Intervention: Conventional Parks' operation
Number of subjects: 102
Study 11577946 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine porous bone mineral combined with enamel matrix derivative (BPBM/EMD)
Number of subjects: 23
Study 11577946 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine porous bone mineral combined with autologous fibrinogen/fibronectin system (BPBM/AFFS)
Number of subjects: 23
Study 11577946 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline)
Number of subjects: 23
Study 9698961 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam (F) 0.8 micrograms.kg‐1.min‐1
Number of subjects: 64
Study 9698961 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (N) 0.3 micrograms.kg‐1.min‐1
Number of subjects: 64
Study 7978472 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (0.25% plain solution, 140 mg, 56 ml)
Number of subjects: 14
Study 7978472 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.25% plain solution, 140 mg, 56 ml)
Number of subjects: 14
Study 3052143 — intervention group
Group type: COMPARATOR
Intervention: Naloxone 0 micrograms/kg/h
Number of subjects: 6
Study 3052143 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 10 micrograms/kg/h
Number of subjects: 6
Study 3052143 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 40 micrograms/kg/h
Number of subjects: 6
Study 30835573 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional injection of bevacizumab
Number of subjects: 30
Study 30835573 — intervention group
Group type: COMPARATOR
Intervention: Intralesional injection of triamcinolone acetonide (TAC)
Number of subjects: 30
Study 31313296 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once daily with water
Number of subjects: 11
Study 31313296 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg with 250 mL of Coca-Cola
Number of subjects: 11